Search details
1.
The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations.
Future Oncol
; 2024 Jan 23.
Article
in English
| MEDLINE | ID: mdl-38258557
2.
Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums.
Future Oncol
; 19(10): 705-714, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-37070428
3.
Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data.
Value Health
; 24(12): 1746-1753, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34838272
4.
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.
Oncology (Williston Park)
; 35(12): 804-811, 2021 12 22.
Article
in English
| MEDLINE | ID: mdl-35089000
5.
Cognitive decline, mortality, and organophosphorus exposure in aging Mexican Americans.
Environ Res
; 160: 132-139, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28982044
6.
Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer.
JCO Precis Oncol
; 8: e2300562, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38547419
7.
Adherence and Persistence Among Risdiplam-Treated Individuals with Spinal Muscular Atrophy: A Retrospective Claims Analysis.
Adv Ther
; 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38709394
8.
Clinical and economic outcomes associated with lymph node examination status in early-stage non-small cell lung cancer: a real-world US study using the SEER-Medicare linked database.
Transl Cancer Res
; 13(4): 1821-1833, 2024 Apr 30.
Article
in English
| MEDLINE | ID: mdl-38737679
9.
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis.
Adv Ther
; 40(3): 903-919, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36534265
10.
Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claimsbased retrospective cohort study.
J Med Econ
; 26(1): 862-870, 2023.
Article
in English
| MEDLINE | ID: mdl-37350423
11.
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Neurol Ther
; 12(5): 1709-1728, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37458897
12.
Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.
Drugs Real World Outcomes
; 10(4): 565-575, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37733192
13.
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection.
Influenza Other Respir Viruses
; 17(12): e13231, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-38098649
14.
Outcomes of antiviral treatment for influenza in type 2 diabetes.
Am J Manag Care
; 29(2): e43-e50, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-36811987
15.
Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza.
J Med Econ
; 25(1): 1061-1067, 2022.
Article
in English
| MEDLINE | ID: mdl-35943115
16.
Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study.
Cancer Med
; 11(1): 139-150, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34874127
17.
Antiviral Use and Health Care Use Among US Patients With Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016-2019.
ACR Open Rheumatol
; 4(7): 631-639, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35559601
18.
Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease.
J Med Econ
; 25(1): 930-939, 2022.
Article
in English
| MEDLINE | ID: mdl-35837794
19.
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
J Manag Care Spec Pharm
; 28(11): 1228-1239, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36282937
20.
Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
J Med Econ
; 25(1): 722-729, 2022.
Article
in English
| MEDLINE | ID: mdl-35608039